Nifedipine

Drug Class & Overview

Mechanism of Action

• Arterial vasodilation - reduces peripheral vascular resistance and blood pressure
• Coronary vasodilation - relieves and prevents coronary artery spasm
• Minimal effect on venous capacitance vessels

• SA node automaticity
• AV node conduction (does not block AV nodal tachycardias)
• Sodium channels

Cardiovascular Effects

• Arterial vasodilation activates baroreceptor reflexes, triggering reflex sympathetic tachycardia - the most prominent of all DHPs.
• Direct myocardial depression seen in vitro does not manifest clinically because vasodilation occurs at plasma concentrations well below those needed to depress contractility.
• Combining nifedipine with a beta-blocker attenuates the reflex tachycardia and is often used in hypertension with coronary artery disease. - Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e

Clinical Indications

1. Essential hypertension (sustained-release formulations only)
2. Variant (Prinzmetal/vasospastic) angina - first-line; more effective and consistent than nitrates for coronary vasospasm
3. Chronic stable angina (in combination)
4. Unstable angina with vasospastic component
5. Raynaud phenomenon - arterial vasodilation relieves digital vasospasm
6. Tocolysis in preterm labor (obstetric use, off-label in many settings) - meta-analyses support efficacy comparable to beta-adrenergic agonists

Dosing

• Sustained-release tabs: Start 30-60 mg PO once daily; may increase to max 120 mg/24 hr
• Dosing above 90 mg/24 hr for angina is limited and should be used with caution

• Sustained-release: 0.2-0.5 mg/kg/24 hr initially (max initial dose 30-60 mg/24 hr) divided Q12-24 hr; max 3 mg/kg/24 hr up to 120 mg/24 hr
• Oral suspension available: 4 mg/mL

• Immediate-release capsules: 10 mg, 20 mg
• Sustained-release tablets (Procardia XL): 30, 60, 90 mg
• Harriet Lane Handbook, 23rd Ed.

Adverse Effects

• Peripheral edema (from arteriolar dilation, increased capillary pressure)
• Reflex tachycardia / palpitations
• Flushing and headache (vasodilatory)
• Dizziness, nausea, syncope
• Severe hypotension (especially with immediate-release form)
• Acute generalized exanthematous pustulosis (rare skin reaction)

Contraindications & Important Cautions

• Immediate-release nifedipine is CONTRAINDICATED in adults for:
  • Hypertensive emergencies
  • Severe obstructive coronary artery disease
  • Recent myocardial infarction
• Retrospective studies showed prompt-release nifedipine increased risk of MI in hypertensive patients - short-acting oral forms should be avoided for chronic hypertension
• Use with caution in: congestive heart failure, aortic stenosis, GI obstruction/narrowing (risk of bezoar), cirrhosis (reduced clearance)
• In children with acute CNS injury: increased risk of stroke, seizure; initial dose should be ≤0.25 mg/kg
• Does NOT improve (and may worsen) mortality in acute MI - unlike diltiazem and verapamil

Drug Interactions

• Itraconazole / ketoconazole (CYP3A4 inhibitors): increase nifedipine levels and effects
• Rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine (CYP3A4 inducers): reduce nifedipine's effects
• Nifedipine may increase levels of: phenytoin, cyclosporine, digoxin
• Enhanced hypotension when combined with other antihypertensives

Comparison to Other Calcium Channel Blockers

Key Clinical Pearls

• Only use sustained-release (long-acting) formulations for chronic hypertension - prompt-release nifedipine has been associated with increased adverse cardiac events.
• It is the preferred drug for variant angina due to profound, consistent coronary vasodilation.
• Reflex tachycardia is more pronounced with nifedipine than any other calcium channel blocker - a beta-blocker combination is often beneficial.
• It does NOT affect AV conduction and has no role in supraventricular tachycardias.
• Recent systematic reviews (2024-2026) include nifedipine in discussions of postpartum hypertension management, where it remains an active comparator - PMID 41421750, PMID 39806714.

Clinical Assessment: Hypertensive Urgency

Diagnosis

• BP: 220/120 mmHg (severely elevated)
• No symptoms for the past 2 weeks
• Age 46 (middle-aged adult)

• Hypertensive encephalopathy (headache, seizures, altered sensorium, vision changes)
• Acute left ventricular failure / pulmonary edema
• Acute kidney injury / hematuria
• Acute coronary syndrome
• Aortic dissection

"Adults presenting with SBP/DBP ≥180/100 mmHg should be classified as having a hypertensive urgency if they are asymptomatic." - Harrison's Principles of Internal Medicine, 22e

Immediate Management Approach

Step 1 - Rule Out End-Organ Damage (Mandatory Before Treatment)

• Fundoscopy - look for papilledema, hemorrhages, exudates
• Neurological exam - mental status, focal deficits
• Cardiac & lung exam - S3 gallop, pulmonary crackles
• ECG - LVH, ischemia
• Labs: serum creatinine, urinalysis (casts/proteinuria), BMP
• Quick history: prior antihypertensive use? missed doses? secondary hypertension clues (abdominal bruit, striae)?

Step 2 - Non-Pharmacological (Often Underused)

• Place patient in a quiet, calm room to rest
• Evidence shows resting alone lowers BP by ≥20/10 mmHg in ~1/3 of patients - equivalent to the effect of a dose of telmisartan 40 mg over 2 hours
• Assess and treat pain - if severe pain is present, give analgesia first to avoid overshoot hypotension once pain resolves

Step 3 - Oral Antihypertensive Therapy

Drug Options for Hypertensive Urgency

Most Commonly Recommended First Choice

"Clonidine, captopril, labetalol, several other short-acting antihypertensive drugs, and even amlodipine, have been used in this setting, but none has a clear advantage over the others." - Brenner and Rector's The Kidney

What NOT to Do

• Do NOT use sublingual short-acting nifedipine - contraindicated; associated with precipitous hypotension, stroke, MI, and death
• Do NOT admit to ICU or give IV antihypertensives - this is not an emergency
• Do NOT try to normalize BP in minutes to hours

Discharge & Follow-Up Plan

1. Observe for 1-2 hours after oral agent - recheck BP
2. If BP trending down and patient remains asymptomatic, discharge home
3. Start (or restart) appropriate long-term antihypertensive regimen
4. Mandatory outpatient follow-up within 1 week - the most important aspect of management
5. Evaluate for secondary causes of hypertension (renovascular, primary aldosteronism, etc.) if BP remains resistant

"The most important aspect of treatment of hypertensive urgency is not achieving a BP goal but rather ensuring adequate follow-up, generally within 1 week." - Comprehensive Clinical Nephrology, 7th Ed.

Summary